🇺🇸 COVID-19 convalescent plasma in United States
430 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 430
Most-reported reactions
- Off Label Use — 200 reports (46.51%)
- Drug Ineffective For Unapproved Indication — 70 reports (16.28%)
- Drug Ineffective — 37 reports (8.6%)
- Covid-19 — 35 reports (8.14%)
- Maternal Exposure During Pregnancy — 18 reports (4.19%)
- Covid-19 Pneumonia — 17 reports (3.95%)
- Foetal Exposure During Pregnancy — 14 reports (3.26%)
- Bronchopulmonary Aspergillosis — 13 reports (3.02%)
- Death — 13 reports (3.02%)
- Exposure During Pregnancy — 13 reports (3.02%)
Other Infectious Diseases approved in United States
Frequently asked questions
Is COVID-19 convalescent plasma approved in United States?
COVID-19 convalescent plasma does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for COVID-19 convalescent plasma in United States?
Lifefactors Zona Franca, SAS is the originator. The local marketing authorisation holder may differ — check the official source linked above.